Previous 10 | Next 10 |
In 2022, ongoing business transformation driven by COVID-19 and flu clinical developments in collaboration with GSK and successful broadening of oncology footprint Early 2023, strong validation of CureVac's proprietary mRNA technology platform from positive preliminary Phase 1 data in ...
2023-04-24 12:25:04 ET CureVac BV ( NASDAQ: CVAC ) is scheduled to announce Q4 earnings results on Tuesday, April 25th, before market open. The consensus EPS Estimate is -$0.29 and the consensus Revenue Estimate is $17.19M For further details see: CureVac BV Q4 2...
2023-04-24 10:24:40 ET Major earning expected before the bell on Tuesday include: General Electric ( GE ) General Motors ( GM ) McDonald's ( MCD ) 3M ( MMM ) Verizon Communications ( VZ ) For further details see: Notable earnings before Tu...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2023 / CureVac N.V. (Nasdaq:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourt...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / March 28, 2023 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's...
2023-03-28 12:05:00 ET The World Health Organization (WHO) issued revised recommendations for prioritizing the use of COVID-19 vaccines on Tuesday, including healthy children and adolescents in a low-priority group for immunizations. The announcement follows a meeting of the agency&...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 10, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the closing of its follow-on public...
Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experience TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 1, 2023 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medi...
CureVac ( NASDAQ: CVAC ) shares dropped ~7% Tuesday likely due to comments Pfizer ( PFE ) made earlier in the day that it expects a 64% drop in revenue from its COVID-19 vaccine. CureVac ( CVAC ) is developing its own mRNA COVID vaccine, and reported positive phase 1 res...
CureVac recognized as a Top 100 innovator in acknowledgment of the company's innovative strength and extensive intellectual property portfolio The company holds one of broadest intellectual property portfolios in mRNA technology TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / Janua...
News, Short Squeeze, Breakout and More Instantly...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent ...
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone pa...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA tec...